Translin-Trax: Considerations for Oncological Therapeutic Targeting.

Autor:	McFarlane RJ; North West Cancer Research Institute, School of Medical Sciences, Bangor University, Deiniol Road, Bangor, Gwynedd LL57 2UW, UK. Electronic address: r.macfarlane@bangor.ac.uk., Wakeman JA; North West Cancer Research Institute, School of Medical Sciences, Bangor University, Deiniol Road, Bangor, Gwynedd LL57 2UW, UK.
Jazyk:	angličtina
Zdroj:	Trends in cancer [Trends Cancer] 2020 Jun; Vol. 6 (6), pp. 450-453. Date of Electronic Publication: 2020 Mar 16.
DOI:	10.1016/j.trecan.2020.02.014
Abstrakt:	Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consider how this complexity could influence therapeutic design strategies. (Copyright © 2020 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu